LOG IN
SIGN UP
MARKET
ATHE
ATHE
Alterity Therapeutics Ltd
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.6767
+0.0070
+1.05%
Closed 16:00 05/27 EDT
OPEN
0.6705
PREV CLOSE
0.6697
HIGH
0.6790
LOW
0.6650
VOLUME
22.09K
TURNOVER
6.43K
52 WEEK HIGH
2.750
52 WEEK LOW
0.5801
MARKET CAP
27.15M
P/E (TTM)
-1.5560
1D
5D
1M
3M
1Y
5Y
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines & Healthcare produc...
PR Newswire · 04/27 11:40
Alterity Therapeutics Secures UK's Approval To Start Phase 2 Trial On ATH434 In Multiple System Atrophy
MT Newswires · 04/27 10:02
Alterity Therapeutics on Wednesday Announced Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting; Said Data Provides Further Validation of the Intended Phase 2 Study Design
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data are being presented in a poster session...
Benzinga · 04/07 10:17
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data are being presented in a poster session...
PR Newswire · 04/07 01:34
Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease
Alterity Therapeutics's (NASDAQ: ATHE) data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease.
Benzinga · 01/28 16:02
Alterity announces publication of animal study on lead asset
Alterity Therapeutics (NASDAQ:ATHE) has added ~10% in the pre-market after announcing that the Journal of Parkinson's Disease published data from an animal study, which was designed to evaluate the effect of its lead candidate
Seekingalpha · 01/28 12:47
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrop...
Benzinga · 01/28 10:44
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and updat...
PR Newswire · 01/27 12:45
No Data
Learn about the latest financial forecast of ATHE. Analyze the recent business situations of Alterity Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 1 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATHE stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
Current 0.6767
EPS
Actual
Estimate
-0.34-0.25-0.17-0.08
Institutional Holdings
Institutions: 22
Institutional Holdings: 770.14K
% Owned: 1.92%
Shares Outstanding: 40.11M
TypeInstitutionsShares
Increased
1
4.04K
New
4
157.79K
Decreased
1
9.10K
Sold Out
6
38.32K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman
Geoffrey Kempler
Chief Executive Officer
David Stamler
Chief Financial Officer
Kathryn Andrews
Secretary
Phillip Hains
Non-Executive Director
Lawrence Gozlan
Non-Executive Independent Director
Peter Marks
Non-Executive Independent Director
Brian Meltzer
No Data
No Data
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company focuses on developing disease modifying treatments for neurodegenerative conditions. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes.
Webull offers kinds of Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ:ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.